Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,384.00    -6.00 (-0.25%)
Bid:
2,380.00
Ask:
2,388.00
Spread: 8.00 (0.336%)
Market Cap: £7.65b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

24 Oct 2023 07:00

RNS Number : 0094R
Bunzl PLC
24 October 2023
 

24 October 2023

 

BUNZL Q3 TRADING STATEMENT

PROFIT IN-LINE WITH EXPECTATIONS; 2023 PROFIT OUTLOOK MAINTAINED

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 30 June 2023.

 

Following Bunzl's strong performance over recent years and continued resilience, the Group continues to perform well. Adjusted operating profit over the quarter was in-line with expectations and the Group reiterates its 2023 adjusted operating profit growth outlook.

 

Group revenue in the third quarter declined by 4.8% at constant exchange rates, with underlying revenue, which is organic growth adjusted for trading days, declining by 4.7%, driven by a continued decline in Covid-19 related product sales; a reduced level of inflation benefit; and wider post-pandemic related normalisation trends which drove expected volume weakness consistent with the prior quarter. One fewer trading day than the comparable period negatively impacted revenue by 0.8%1. Acquisitions contributed growth of 2.0% at constant exchange rates, whilst the disposal of our UK healthcare business impacted revenue by 1.3%. Overall, at actual exchange rates, given the weakness of sterling in the prior year, Group revenue declined by 8.8% over the quarter. Operating margin over the quarter was very strong, remaining substantially higher than compared to the pre-pandemic period in 2019, and slightly ahead of the Group's expectations.

 

We reiterate our confidence in the Group's 2023 adjusted operating profit being moderately higher than in 2022 at constant exchange rates. We expect Group revenue, at constant exchange rates, to be slightly lower than in 2022, with the benefit of announced acquisitions offset by some organic decline, following strong organic growth in recent years, and a small impact from the UK healthcare disposal. Operating margin in 2023 is now expected to reach the record level seen in recent years.

 

In September 2023, Bunzl signed an agreement to acquire CT Group, a distributor of surgical and medical devices and provider of value-added logistics services to health providers in Brazil which will enhance Bunzl's national presence and expand our product offering. In 2022, the higher margin business generated revenue of BRL 269 million (c.£42 million). Completion of the acquisition is subject to competition authority clearance.

 

Towards the end of August 2023, Bunzl completed the acquisition of Pittman Traffic & Safety Equipment in Ireland, a distributor of safety and asset protection solutions, such as bollards, speed bumps and workplace barriers. This acquisition supports the expansion of our North America based McCue business, which already has a UK presence. Pittman Traffic & Safety Equipment generated revenue of EUR 7 million (c.£6 million) in 2022.

 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Our performance continues to highlight the strength and resilience of the Group's business model, with revenue over the quarter 29% higher, and operating margin substantially higher, than the comparable period in 2019 at constant exchange rates. I remain confident in our ability to sustain a higher operating margin compared to pre-pandemic levels, supported by the acquisitions we have made over the period. Furthermore, today we announce our 13th and 14th acquisitions of 2023, with a total year-to-date committed spend of more than £425 million. I remain excited by the Group's medium-term opportunities, which continue to be driven by our proven compounding growth strategy and active acquisition pipeline, supported by a strong balance sheet."

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

 

Teneo

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

1. Net of the benefit of growth in excess of 26% per annum in hyperinflationary economies, largely in Turkey, which contributed a small increase of 0.1%.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUBDGIBDDGXX
Date   Source Headline
3rd Jun 202610:45 amRNSDirector/PDMR Shareholding
1st Jun 202610:15 amRNSTotal Voting Rights
1st Jun 202610:00 amRNSAdmission to Trading
8th May 20264:13 pmRNSDirector/PDMR Shareholding
7th May 20262:43 pmRNSDirector/PDMR Shareholding
6th May 202610:05 amRNSDirector/PDMR Shareholding
1st May 202611:15 amRNSTotal Voting Rights
22nd Apr 20264:15 pmRNSResult of AGM
22nd Apr 20267:00 amRNSTrading Statement
13th Apr 20264:00 pmRNSDirector/PDMR Shareholding
9th Apr 202612:01 pmRNSDirector/PDMR Shareholding
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 202611:00 amRNSTotal Voting Rights
31st Mar 20264:50 pmRNSDirector/PDMR Shareholding
20th Mar 20262:28 pmRNSDirector/PDMR Shareholding
18th Mar 20265:26 pmRNSDirector/PDMR Shareholding
17th Mar 20264:20 pmRNSAnnual Financial Report
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
10th Mar 20263:30 pmRNSDirector Declaration
10th Mar 20263:30 pmRNSDirector Declaration
9th Mar 202610:20 amRNSDirector/PDMR Shareholding
5th Mar 20265:15 pmRNSDirector/PDMR Shareholding
4th Mar 20264:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20264:45 pmRNSDirector/PDMR Shareholding
2nd Mar 202611:00 amRNSTotal Voting Rights
2nd Mar 202610:00 amRNSDividend Declaration
2nd Mar 20267:00 amRNSFinal Results
3rd Feb 20265:00 pmRNSDirector/PDMR Shareholding
2nd Feb 202612:45 pmRNSTotal Voting Rights
13th Jan 20265:00 pmRNSDirector/PDMR Shareholding
7th Jan 20265:15 pmRNSDirector/PDMR Shareholding
6th Jan 202611:15 amRNSDirector/PDMR Shareholding
2nd Jan 202610:45 amRNSTotal Voting Rights
17th Dec 20257:00 amRNSTrading Statement
3rd Dec 202512:00 pmRNSDirector/PDMR Shareholding
1st Dec 202511:00 amRNSTotal Voting Rights
27th Nov 20259:00 amRNSAdditional Listing
26th Nov 20253:34 pmRNSPublication of Admission Particulars.
21st Nov 20255:30 pmRNSHolding(s) in Company
17th Nov 20255:34 pmRNSHolding(s) in Company
13th Nov 20259:00 amRNSAdditional Listing
5th Nov 20259:45 amRNSDirector/PDMR Shareholding
3rd Nov 20254:00 pmRNSHolding(s) in Company
3rd Nov 20253:29 pmRNSTotal Voting Rights
3rd Nov 20259:30 amRNSBlock listing Interim Review
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.